GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence ("AI") and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, CEO, will participate in a fireside chat and one-on-one meetings at BTIG’s Annual Virtual Biotechnology Conference, being held Tuesday, July 29 through Wednesday, July 3 ...

GAITHERSBURG, Md., July 18, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics,, is pleased to invite investors to a webinar on July 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature BullFrog AI’s Founder and CEO, Vin Singh. Attendees will g ...

New module addresses multi-billion-dollar data quality challenge in life sciences by automating data cleansing, standardization, and transformation for AI readiness Built for scale, security, and human in the loop domain expertise, the enterprise-wide solution is poised to transform drug development for the world’s largest biopharma organizations GAITHERSBURG, Md., July 17, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug ...

Core Insights - BullFrog AI Holdings, Inc. has launched the BullFrog Data Networks™ Solutions Library, an enterprise-wide solution aimed at transforming drug development for large biopharma organizations through AI and machine learning [1][6] Group 1: Product Overview - The BullFrog Data Networks™ Solutions Library is set to launch in late 2025 and is tailored for large-scale pharmaceutical, biotechnology, and life sciences organizations, providing secure infrastructure to extract insights from extensive biomedical datasets [2] - The platform is organized into specialized modules focusing on critical areas of drug discovery, such as target selection and clinical trial optimization, allowing clients to customize their decision support systems [2][6] - The solution is built on the bfLEAP™ causal AI engine, enhancing the ability to analyze complex biological data and streamline therapeutics development [1][10] Group 2: Technical Infrastructure - The library supports native deployment across major cloud platforms including Google Cloud Platform, Microsoft Azure, and Amazon Web Services, ensuring scalability, uptime, and data security [3] - This cloud-native architecture allows for rapid deployment and compliance with global data privacy standards, facilitating seamless data access and integration for R&D teams [4][5] Group 3: Market Position and Growth Potential - The BullFrog Data Networks Solutions Library aims to reduce R&D costs and failure rates for biopharma companies, positioning BullFrog AI as a leader in AI-driven drug discovery [6] - The global AI in drug discovery market is projected to reach $35.4 billion by 2034, growing at a CAGR of 29.6%, indicating a strong demand for scalable, data-driven solutions [8]

Core Insights - BullFrog AI Holdings, Inc. is leveraging AI and machine learning to enhance drug development processes, showcasing its leadership in AI-driven bioinformatics through the participation of Dr. Juan Felipe Beltrán in an upcoming webinar [1][2] Group 1: Company Overview - BullFrog AI focuses on technology-enabled drug development, utilizing AI and machine learning to improve the efficiency and success rates of pharmaceuticals and biologics [1][6] - The company’s proprietary bfLEAP™ platform and BullFrog Data Networks™ are designed to provide actionable insights from complex biological data, addressing the challenge that only 12% of drugs entering Phase 1 clinical trials successfully reach the market [4] Group 2: Webinar Details - Dr. Beltrán will discuss critical issues in AI-driven bioinformatics, including mismanagement of compositional data, overinterpretation of machine learning feature importance, and misapplication of generative AI [3] - The webinar aims to provide practical strategies for bioinformaticians, biostatisticians, data scientists, and translational scientists to improve decision-making and confidence in analytical results [5] Group 3: Market Opportunity - The company emphasizes the significant market opportunity in enhancing drug discovery processes, which is crucial for investors recognizing the potential in AI-driven solutions for biopharma [2]

GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced a strategic collaboration with Sygnature Discovery, a leading UK-based contract research organization (CRO) specializing in drug discovery. Through this collaboration, Sygnature will intr ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Nevada 84-4786155 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41600 BULLFROG AI HOL ...

GAITHERSBURG, Md., April 17, 2025 (GLOBE NEWSWIRE) -- Bullfrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on April 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Vin Singh, CEO of Bullfrog AI. Attendees will gain insight ...

GAITHERSBURG, Md., April 17, 2025 (GLOBE NEWSWIRE) -- Bullfrog AI Holdings, Inc. (NASDAQ:BFRG, BFRGW)) ("Bullfrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, is pleased to invite investors to a webinar on April 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Vin Singh, CEO of Bullfrog AI. Attendees will gain insight ...

For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from [ ] to [ ] Commission file number 001-41600 BULLFROG AI HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...